Stock ABBVD ABBVIE INC.
Add to a list
To use this feature you must be a member
Log inSign up

Ratings AbbVie Inc. Buenos Aires S.E.

Equities

ABBVD

ARBCOM4603M9

End-of-day quote Buenos Aires S.E.
Other stock markets
 03:30:00 27/06/2024 am IST 		5-day change 1st Jan Change
18.05 USD +4.64% Intraday chart for AbbVie Inc. +6.18% +18.75%
28/06 Genmab, AbbVie's Lymphoma Therapy Recommended for Approval in EU MT
28/06 AbbVie, Genmab Receive Positive European Opinion on Marketing Authorization for Possible Lymphoma Treatment MT

Summary

  • Overall, the company has poor fundamentals for a medium to long-term investment strategy.

Strengths

  • The company's profit outlook over the next few years is a strong asset.
  • Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
  • Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
  • Over the past year, analysts have regularly revised upwards their sales forecast for the company.
  • Analysts' price targets are all relatively close, reflecting good visibility on the company's valuation.

Weaknesses

  • The group shows a rather high level of debt in proportion to its EBITDA.
  • With an expected P/E ratio at 29.91 and 23.46 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
  • Based on current prices, the company has particularly high valuation levels.
  • In relation to the value of its tangible assets, the company's valuation appears relatively high.
  • For the past year, analysts have significantly revised downwards their profit estimates.

Ratings chart - Surperformance

Sector: Pharmaceuticals

1st Jan change Capi. Investor Rating ESG Refinitiv
ABBVIE INC. Stock AbbVie Inc.
+18.75% 30TCr -
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+55.32% 82TCr
C+
JOHNSON & JOHNSON Stock Johnson & Johnson
-6.75% 35TCr
C+
MERCK & CO., INC. Stock Merck & Co., Inc.
+13.56% 31TCr
B-
ASTRAZENECA PLC Stock AstraZeneca PLC
+16.57% 24TCr
B+
ROCHE HOLDING AG Stock Roche Holding AG
+2.04% 22TCr
A+
NOVARTIS AG Stock Novartis AG
+13.31% 22TCr
B-
AMGEN INC. Stock Amgen Inc.
+8.48% 17TCr
C+
PFIZER, INC. Stock Pfizer, Inc.
-2.81% 16TCr
C+
SANOFI Stock Sanofi
+0.20% 12TCr
B+
Investor Rating
Trading Rating
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
Yield

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. ABBV Stock
  4. ABBVD Stock
  5. Ratings AbbVie Inc.